Effects of pediatric cancer therapy on the musculoskeletal system

1997 ◽  
Vol 27 (8) ◽  
pp. 623-636 ◽  
Author(s):  
B. D. Fletcher
Keyword(s):  
Cancer Therapy ◽  
Musculoskeletal System ◽  
Pediatric Cancer

Late and Acute Effects of Pediatric Cancer Therapy on the Oral Cavity

2013 ◽  
pp. 321-330
Author(s):  
Christopher Rowland ◽  
Cesar A. Migliorati ◽  
Sue C. Kaste
Keyword(s):  
Cancer Therapy ◽  
Oral Cavity ◽  
Pediatric Cancer ◽  
Acute Effects

Pediatric cancer therapy and fertility

2011 ◽  
pp. 73-82
Author(s):  
Pinki K. Prasad ◽  
Jill Simmons ◽  
Debra Friedman
Keyword(s):  
Cancer Therapy ◽  
Pediatric Cancer

Pediatric Cancer Therapy

1981 ◽  
Vol 3 (2) ◽  
pp. 221 ◽  
Author(s):  
C. Philip Steuber
Keyword(s):  
Cancer Therapy ◽  
Pediatric Cancer

Parents’ understanding of the risk of late effects of pediatric cancer therapy.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 10522-10522 ◽  
Author(s):  
Katie Greenzang ◽  
Angel Cronin ◽  
Tammy I Kang ◽  
Jennifer W. Mack
Keyword(s):  
Cancer Therapy ◽  
Pediatric Cancer ◽  
Late Effects

PEDIATRIC CANCER THERAPY

1980 ◽  
Vol 9 (12) ◽  
pp. 62-63
Author(s):  
Donald J Fernbach
Keyword(s):  
Cancer Therapy ◽  
Pediatric Cancer

scholarly journals Hyperglycemia During Childhood Cancer Therapy: Incidence, Implications, and Impact on Outcomes

2019 ◽  
Vol 2019 (54) ◽  
pp. 132-138 ◽  
Author(s):  
Allison Grimes ◽  
Ashraf Mohamed ◽  
Jenna Sopfe ◽  
Rachel Hill ◽  
Jane Lynch
Keyword(s):  
Risk Factors ◽  
Cancer Therapy ◽  
Adverse Effects ◽  
Cancer Treatment ◽  
Childhood Cancer ◽  
Pediatric Cancer ◽  
Immune Checkpoint Inhibitors ◽  
Systematic Approach ◽  
Checkpoint Inhibitors ◽  
Limited Data

Abstract Hyperglycemia is a known complication of therapies used in the treatment of childhood cancer, particularly glucocorticoids and asparaginase. It has been linked to increased infection and reduced survival. With more limited data on hyperglycemia during childhood cancer treatment compared with adult cancer, impact on outcomes is less clear in this population. As additional glycemic-altering cancer agents including immune checkpoint inhibitors and targeted therapies make their way into pediatric cancer treatment, there is a more pressing need to better understand the mechanisms, risk factors, and adverse effects of hyperglycemia on the child with cancer. Thus, we utilized a systematic approach to review the current understanding of the incidence, implications, and outcomes of hyperglycemia during childhood cancer therapy.

scholarly journals Endocrine Health Problems Detected in 764 Patients Evaluated in a Late Effects Clinic

2017 ◽  
Vol 10 (3) ◽  
pp. 958-963
Author(s):  
Maria Conceição Pereira ◽  
Joana S. Pereira ◽  
Daniela Dias ◽  
Sara Donato ◽  
Duarte Salgado
Keyword(s):  
Cancer Therapy ◽  
Cancer Survivors ◽  
Outcome Measures ◽  
Pediatric Cancer ◽  
Late Effects ◽  
Medical Records ◽  
Alkylating Agents ◽  
Growth Spurt ◽  
Endocrine Effects ◽  
Pediatric Cancer Survivors

Background: Many pediatric cancer survivors have endocrine conditions. After treatment with alkylating agents, steroids, methotrexate, and radiation, several endocrine dysfunctions may appear. Surveillance for late effects is recommended by guidelines worldwide. Objective: The objective of this study was to describe the endocrine outcomes of 764 patients followed during a 20 years’ period in our out-patient clinic. Design: We retrospectively reviewed the medical records. Patients: The study included 764 patients whose oncological or hematological dangerous diseases appeared before they were 18 years old. Larger groups were constituted by leukemias, central nervous tumors, and lymphomas. Outcome Measures: The frequency and types of endocrine conditions were analyzed. Results: 1,091 endocrine conditions were observed in all groups. The most common types of endocrine conditions were problems with growth and the thyroid. We found puberty abnormalities and bone problems in third and fourth places of frequency. ACTH insufficiency was found in seventh place. Conclusion: Endocrine dysfunctions are very common in survivor populations. Endocrinologists should be aware of international guidelines and make an effort to optimize screening and treatment of endocrine effects of cancer therapy. The crucial period is the puberty with growth spurt failure and accelerated maturity both of which can bring future social and professional difficulties.

Sign in / Sign up

Export Citation Format

Share Document